TINF2 and cancer: To date, only a few clinical studies have specifically evaluated the association between cancer risk and specific germline mutations in patients with DC/TBDs and showed that about 1%–4% patients had an underlying TINF2 mutation (Vulliamy et al., 2011; Schratz et al, 2020; Niewisch et al, 2022).